Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination With Induction Chemotherapy

NCT02724163 is registered in ClinicalTrials.gov with University of Birmingham as lead sponsor.

NCT NCT02724163
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02724163 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination With Induction Chemotherapy
Lead sponsor
University of Birmingham
Phase
Phase 3
Overall status
Active, not recruiting
Start date
April 30, 2016
Completion date
December 31, 2032
Enrollment
700 (estimated)
Sites
68

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukaemia